Airline Stocks – Form 424B2 UBS AG

---

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

---

The information in this preliminary pricing supplement is not complete
and may be changed. We may not sell these Notes until the pricing supplement, the accompanying product supplement and the accompanying
prospectus (collectively, the “Offering Documents”) are delivered in final form. The Offering Documents are not an offer to
sell these Notes and we are not soliciting offers to buy these Notes in any state where the offer or sale is not permitted.

Subject to Completion PRELIMINARY PRICING SUPPLEMENT Dated April 6, 2021 Filed Pursuant to Rule 424(b)(2) Registration Statement No. 333-253432 (To Prospectus dated February 24, 2021 and Product Supplement dated February 24, 2021)

UBS AG Trigger Autocallable Contingent Yield Notes

UBS AG $• linked to the common stock of JetBlue Airways Corporation due on or about
April 13, 2023

Investment
Description

UBS AG Trigger Autocallable Contingent Yield Notes (the “Notes”)
are unsubordinated, unsecured debt obligations issued by UBS AG (“UBS” or the “issuer”) linked to the common stock
of JetBlue Airways Corporation (the “underlying asset”). UBS will pay a contingent coupon on a coupon payment date only if
the closing level of the underlying asset on the applicable observation date (including the final valuation date), is equal to or greater
than the coupon barrier. Otherwise, no contingent coupon will be paid for the relevant coupon payment date. UBS will automatically call
the Notes early if the closing level of the underlying asset on any observation date (beginning after 6 months) prior to the final valuation
date is equal to or greater than the call threshold level, which is a level of the underlying asset equal to a percentage of the initial
level, as indicated below. If the Notes are subject to an automatic call, UBS will pay you on the coupon payment date corresponding to
such observation date (the “call settlement date”) a cash payment per Note equal to the principal amount plus any contingent
coupon otherwise due, and no further payments will be owed to you under the Notes. If the Notes are not subject to an automatic call and
the closing level of the underlying asset on the final valuation date (the “final level”) is equal to or greater than the
downside threshold, at maturity, UBS will pay you a cash payment per Note equal to the principal amount, in addition to any contingent
coupon otherwise due with respect to the final valuation date. If, however, the Notes are not subject to an automatic call and the final
level is less than the downside threshold, at maturity, UBS will deliver to you a number of shares of the underlying asset per Note equal
to the quotient of (i) the principal amount divided by (ii) the initial level (the “share delivery amount”), the value of
which is expected to be worth significantly less than your principal amount, resulting in a loss of a significant portion or all of your
initial investment. Any fractional share included in the share delivery amount will be paid in cash at an amount equal to the product
of the fractional share and the final level. For the avoidance of doubt, if the share delivery amount is less than 1.0000, at maturity
you will receive an amount in cash per Note, if anything, equal to the product of the share delivery amount and the final level. Investing
in the Notes involves significant risks. You may lose a significant portion or all of your initial investment and may not receive any
contingent coupon during the term of the Notes. Generally, a higher contingent coupon rate on a Note is associated with a greater risk
of loss and a greater risk that you will not receive contingent coupons over the term of the Notes. The contingent repayment of principal
applies only at maturity. Any payment or delivery on the Notes, including any repayment of principal, is subject to the creditworthiness
of UBS. If UBS were to default on its obligations, you may not receive any amounts or shares owed to you under the Notes and you could
lose all of your initial investment.

Notice to investors: the Notes are significantly riskier than
conventional debt instruments. The issuer is not necessarily obligated to repay the principal amount of the Notes at maturity, and the
Notes may have the same downside market risk as that of the underlying asset. This market risk is in addition to the credit risk inherent
in purchasing a debt obligation of UBS. You should not purchase the Notes if you do not understand or are not comfortable with the significant
risks involved in investing in the Notes.

You should carefully consider the risks described under “Key
Risks” beginning on page 5 and under “Risk Factors” beginning on page PS-9 of the accompanying product supplement. Events
relating to any of those risks, or other risks and uncertainties, could adversely affect the market value of, and the return on, your
Notes. You may lose a significant portion or all of your initial investment in the Notes. The Notes will not be listed or displayed on
any securities exchange or any electronic communications network.

Note
Offering

The final terms of the Notes will be set on the trade date.

Underlying Asset	Bloomberg Ticker	Contingent Coupon Rate	Initial Level	Call Threshold Level	Downside Threshold	Coupon Barrier	Share Delivery Amount(1)	CUSIP	ISIN
Common stock of JetBlue Airways Corporation	JBLU	8.10% per annum	$•	100.00% of the Initial Level	55.00% of the Initial Level	55.00% of the Initial Level	• shares per Note	90276BXF5	US90276BXF56

⁽¹⁾ Equal to $1,000 divided by the initial level, rounded
to the nearest ten thousandth of one share. If you receive the share delivery amount at maturity, any fractional share included in the
share delivery amount will be paid in cash at an amount equal to the product of the fractional share and the final level. The share delivery
amount and initial level are subject to adjustments in the case of certain corporate events, as described in the accompanying product
supplement under “General Terms of the Securities — Antidilution Adjustments for Securities Linked to an Underlying Equity
or Equity Basket Asset” and “— Reorganization Events for Securities Linked to an Underlying Equity or Equity Basket
Asset”.

The estimated initial value of the Notes as of the trade date is
expected to be between $930.70 and $960.70. The range of the estimated initial value of the Notes was determined on the date hereof by
reference to UBS’ internal pricing models, inclusive of the internal funding rate. For more information about secondary market offers
and the estimated initial value of the Notes, see “Key Risks — Estimated Value Considerations” and “— Risks
Relating to Liquidity and Secondary Market price Considerations” beginning on page 6 herein.

See “Additional Information about UBS and the Notes”
on page ii. The Notes will have the terms set forth in the accompanying product supplement relating to the Notes, dated February 24, 2021,
the accompanying prospectus dated February 24, 2021 and this document.

Neither the Securities and Exchange Commission nor any other
regulatory body has approved or disapproved of these Notes or passed upon the adequacy or accuracy of this document, the accompanying
product supplement or the accompanying prospectus. Any representation to the contrary is a criminal offense.

The Notes are not bank deposits and are not insured by the Federal
Deposit Insurance Corporation or any other governmental agency.

Offering of Notes	Issue price to Public(1)		Underwriting Discount(1)(2)		Proceeds to UBS AG(2)
	Total	Per Note	Total	Per Note	Total	Per Note
Notes linked to the common stock of JetBlue Airways Corporation	$•	$1,000.00	$•	$17.50	$•	$982.50

⁽¹⁾ Notwithstanding the underwriting discount received
by one or more third-party dealers from UBS Securities LLC described below, certain registered investment advisers or fee-based advisory
accounts unaffiliated from UBS may purchase Notes from a third-party dealer at a purchase price of at least $982.50 per Note, and such
third-party dealer, with respect to such sales, may forgo some or all of the underwriting discount.

⁽²⁾ Our affiliate, UBS Securities LLC, will receive
an underwriting discount of $17.50 per Note sold in this offering. UBS Securities LLC intends to re-allow the full amount of this discount
to one or more third-party dealers. Certain of such third-party dealers may resell the Notes to other securities dealers at the issue
price to the public less an underwriting discount of up to the underwriting discount indicated in the above table.

UBS Securities LLC

UBS Investment Bank

 

Additional
Information about UBS and the Notes

UBS has filed a registration statement (including a prospectus, as supplemented by a product supplement for the Notes) with the Securities and Exchange Commission (the “SEC”), for the Notes to which this document relates. You should read these documents and any other documents relating to the Notes that UBS has filed with the SEC for more complete information about UBS and the Notes. You may obtain these documents for free from the SEC website at www.sec.gov. Our Central Index Key, or CIK, on the SEC website is 0001114446.

You may access these documents on the SEC website at www.sec.gov as follows:

References to “UBS”, “we”, “our” and “us” refer only to UBS AG and not to its consolidated subsidiaries and references to the “Trigger Autocallable Contingent Yield Notes” or the “Notes” refer to the Notes that are offered hereby. Also, references to the “accompanying product supplement” or “Market-Linked Securities product supplement” mean the UBS product supplement, dated February 24, 2021 and references to the “accompanying prospectus” mean the UBS prospectus, titled “Debt Securities and Warrants”, dated February 24, 2021.

This document, together with the documents listed above, contains the terms of the Notes and supersedes all other prior or contemporaneous oral statements as well as any other written materials including all other prior pricing terms, correspondence, trade ideas, structures for implementation, sample structures, brochures or other educational materials of ours. You should carefully consider, among other things, the matters set forth in “Key Risks” herein and in “Risk Factors” in the accompanying product supplement, as the Notes involve risks not associated with conventional debt securities. We urge you to consult your investment, legal, tax, accounting and other advisors concerning an investment in the Notes. If there is any inconsistency between the terms of the Notes described in the accompanying prospectus, the accompanying product supplement and this document, the following hierarchy will govern: first, this document; second, the accompanying product supplement; and last, the accompanying prospectus.

UBS reserves the right to change the terms of, or reject any offer to purchase, the Notes prior to their issuance. In the event of any changes to the terms of the Notes, UBS will notify you and you will be asked to accept such changes in connection with your purchase. You may also choose to reject such changes in which case UBS may reject your offer to purchase.

 

Investor
Suitability

The suitability considerations identified above are not
exhaustive. Whether or not the Notes are a suitable investment for you will depend on your individual circumstances. You are urged to
consult your investment, legal, tax, accounting and other advisors and carefully consider the suitability of an investment in the Notes
in light of your particular circumstances. You should review “Information About the Underlying Asset” herein for more information
on the underlying asset. You should also review carefully the “Key Risks” section herein for risks related to an investment
in the Notes.

 

Preliminary
Terms

Investment
Timeline

 

Trade Date		The initial level of the underlying asset is observed and the final terms of the Notes are set.
¯
Observation Dates (Quarterly, callable beginning after 6 months)		If the closing level of the underlying asset is equal to or greater than the coupon barrier on any observation date (including the final valuation date), UBS will pay you a contingent coupon on the corresponding coupon payment date. The Notes will be subject to an automatic call if the closing level of the underlying asset on any observation date (beginning after 6 months) other than the final valuation date is equal to or greater than the call threshold level. If the Notes are subject to an automatic call, UBS will pay you on the call settlement date a cash payment per Note equal to the principal amount plus any contingent coupon otherwise due. Following an automatic call, no further payments will be made on the Notes.
¯
Maturity Date		The final level is observed on the final valuation date. If the Notes are not subject to an automatic call and the final level is equal to or greater than the downside threshold, UBS will pay you a cash payment per Note equal to: Principal Amount of $1,000 If the Notes are not subject to an automatic call and the final level is less than the downside threshold, UBS will deliver to you a number of shares of the underlying asset (with cash paid in lieu of any fractional share) per Note, equal to: Share Delivery Amount In this scenario, you will receive the share delivery amount, the value of which is expected to be worth significantly less than the principal amount, resulting in a loss of a significant portion or all of your initial investment. Specifically, the percentage loss on your initial investment as of the final valuation date will be equal to the percentage decline of the underlying asset from the initial level to the final level.

 

Investing in the Notes involves significant risks. You
may lose a significant portion or all of your initial investment. Any payment or delivery on the Notes, including any repayment of principal,
is subject to the creditworthiness of UBS. If UBS were to default on its obligations, you may not receive any payments or deliveries owed
to you under the Notes and you could lose all of your initial investment.

If the Notes are not subject to an automatic call, you
may lose a significant portion or all of your initial investment. Specifically, if the Notes are not subject to an automatic call and
the final level is less than the downside threshold, UBS will deliver to you a number of shares of the underlying asset per Note equal
to the share delivery amount, the value of which is expected to be worth significantly less than the principal amount, resulting in a
loss of a significant portion or all of your initial investment. In this scenario, the percentage loss on your initial investment as of
the final valuation date will be equal to the percentage decline of the underlying asset from the initial level to the final level.

 

Observation
Dates⁽¹⁾ and Coupon Payment Dates⁽¹⁾⁽²⁾

Observation Dates	Coupon Payment Dates
July 8, 2021*	July 13, 2021*
October 8, 2021*	October 14, 2021
January 10, 2022	January 13, 2022
April 8, 2022	April 13, 2022
July 8, 2022	July 13, 2022
October 11, 2022	October 14, 2022
January 9, 2023	January 12, 2023
Final Valuation Date	Maturity Date

 

*

The Notes are not callable until the first potential call settlement date, which is October 14, 2021.

(1)

Subject to the market disruption event provisions set forth in the accompanying product supplement.

(2)

Three business day(s) following each observation date, except that the coupon payment date for the final valuation date is the maturity date.

 

Key
Risks

An investment in the Notes involves significant risks. Investing
in the Notes is not equivalent to a hypothetical investment in the underlying asset. Some of the key risks that apply to the Notes are
summarized below, but we urge you to read the more detailed explanation of risks relating to the Notes in the “Risk Factors”
section of the accompanying product supplement. We also urge you to consult your investment, legal, tax, accounting and other advisors
concerning an investment in the Notes.

Risks Relating to Return Characteristics

¨

Risk of loss at maturity — The Notes differ from ordinary debt securities in that UBS will not necessarily make periodic coupon payments or repay the full principal amount of the Notes at maturity. If the Notes are not subject to an automatic call and the final level is less than the downside threshold, at maturity UBS will deliver to you a number of shares per Note equal to the share delivery amount (with cash paid in lieu of any fractional share), the value of which is expected to be worth significantly less than your principal amount, resulting in a loss of a significant portion or all of your initial investment. If you receive the share delivery amount, the percentage loss on your initial investment, as of the final valuation date, will be equal to the percentage decline of the level of the underlying asset from the initial level to the final level. Additionally, in the event that the final level is less than the downside threshold, any decline of the level of the underlying asset from the final valuation date to the maturity date will cause your return on the Notes to be less than the return you would have received had UBS instead paid you the cash value of the share delivery amount as of the final valuation date.

¨

The stated payout from the issuer applies only if you hold your Notes to maturity — You should be willing to hold your Notes to maturity. If you are able to sell your Notes prior to an automatic call or maturity in the secondary market, you may have to sell them at a loss relative to your initial investment even if the level of the underlying asset at such time is equal to or greater than the downside threshold. All payments and deliveries on the Notes are subject to the creditworthiness of UBS.

¨

You may not receive any contingent coupons with respect to your Notes — UBS will not necessarily make periodic coupon payments on the Notes. If the closing level of the underlying asset is less than the coupon barrier on an observation date, UBS will not pay you the contingent coupon applicable to such observation date. If the closing level of the underlying asset is less than the coupon barrier on each observation date, UBS will not pay you any contingent coupons during the term of, and you will not receive a positive return on, your Notes. Generally, this non-payment of the contingent coupon coincides with a period of greater risk of principal loss on your Notes.

¨

Your potential return on the Notes is limited to any contingent coupons, you will not participate in any appreciation of the underlying asset and you will not receive dividend payments on the underlying asset or have the same rights as holders of the underlying asset — The return potential of the Notes is limited to the pre-specified contingent coupon rate, regardless of the appreciation of the underlying asset. In addition, your return on the Notes will vary based on the number of observation dates, if any, on which the requirements of the contingent coupon have been met prior to maturity or an automatic call. Because the Notes may be subject to an automatic call as early as the first potential call settlement date, the total return on the Notes could be less than if the Notes remained outstanding until maturity. Further, if the Notes are subject to an automatic call, you will not receive any contingent coupons or any other payment in respect of any coupon payment date after the call settlement date, and your return on the Notes could be less than if the Notes remained outstanding until maturity. As a result, the return on an investment in the Notes could be less than the return on a hypothetical investment in the underlying asset. In addition, as an owner of the Notes, you will not receive or be entitled to receive any dividend payments or other distributions on the underlying asset during the term of the Notes, and any such dividends or distributions will not be factored into the calculation of any payments or deliveries on your Notes. Similarly, unless and until you receive the share delivery amount on the maturity date, you will not have voting rights or any other rights of a holder of the underlying asset.

¨

A higher contingent coupon rate or lower downside threshold or coupon barrier may reflect greater expected volatility of the underlying asset, and greater expected volatility generally indicates an increased risk of loss at maturity — The economic terms for the Notes, including the contingent coupon rate, coupon barrier and downside threshold, are based, in part, on the expected volatility of the underlying asset at the time the terms of the Notes are set. “Volatility” refers to the frequency and magnitude of changes in the level of the underlying asset. The greater the expected volatility of the underlying asset as of the trade date, the greater the expectation is as of that date that the closing level of the underlying asset could be less than the coupon barrier on the observation dates and that the final level could be less than the downside threshold and, as a consequence, indicates an increased risk of not receiving a contingent coupon and an increased risk of loss, respectively. All things being equal, this greater expected volatility will generally be reflected in a higher contingent coupon rate than the yield payable on our conventional debt securities with a similar maturity or on otherwise comparable securities, and/or a lower downside threshold and/or coupon barrier than those terms on otherwise comparable securities. Therefore, a relatively higher contingent coupon rate may indicate an increased risk of loss. Further, a relatively lower downside threshold and/or coupon barrier may not necessarily indicate that the Notes have a greater likelihood of a return of principal at maturity and/or paying contingent coupons. You should be willing to accept the downside market risk of the underlying asset and the potential to lose a significant portion or all of your initial investment.

¨

Reinvestment risk — The Notes will be subject to an automatic call if the closing level of the underlying asset is equal to or greater than the call threshold level on certain observation dates prior to the final valuation date, as set forth under “Observation Dates and Coupon Payment Dates“ herein. Because the Notes could be subject to an automatic call as early as the first potential call settlement date, the term of your investment may be limited. In the event that the Notes are subject to an automatic call, there is no guarantee that you would be able to reinvest the proceeds at a comparable rate of return and/or with a comparable contingent coupon rate for a similar level of risk. In

addition, to the extent you are
able to reinvest such proceeds in an investment comparable to the Notes, you may incur transaction costs such as dealer discounts and
hedging costs built into the price of the new securities. Generally, however, the longer the Notes remain outstanding, the less likely
the Notes will be subject to an automatic call due to the decline of the level of the underlying asset and the shorter time remaining
for the level of the underlying asset to recover. Such periods generally coincide with a period of greater risk of principal loss on your
Notes.

Risks Relating to Characteristics
of the Underlying Asset

¨

Single equity risk — The return on the Notes, which may be negative, is directly linked to the performance of the underlying asset. The level of the underlying asset can rise or fall sharply due to factors specific to the underlying asset and its issuer (the “underlying asset issuer”), such as stock or commodity price volatility, earnings, financial conditions, corporate, industry and regulatory developments, management changes and decisions and other events, as well as general market factors, such as general stock and commodity market volatility and levels, interest rates and economic, political and other conditions. Recently, the coronavirus infection has caused volatility in the global financial markets and a slowdown in the global economy. Coronavirus or any other communicable disease or infection may adversely affect the underlying asset issuer and, therefore, the underlying asset. You, as an investor in the Notes, should conduct your own investigation into the underlying asset issuer and the underlying asset for your Notes. For additional information regarding the underlying asset and the underlying asset issuer, please see “Information About the Underlying Asset” herein and the underlying asset issuer’s SEC filings referred to in that section. We urge you to review financial and other information filed periodically by the underlying asset issuer with the SEC.

¨

There can be no assurance that the investment view implicit in the Notes will be successful — It is impossible to predict whether and the extent to which the level of the underlying asset will rise or fall. There can be no assurance that the closing level of the underlying asset will be equal to or greater than the coupon barrier on each observation date or, if the Notes are not subject to an automatic call, that the final level will be equal to or greater than the downside threshold. The level of the underlying asset will be influenced by complex and interrelated political, economic, financial and other factors that affect the underlying asset issuer. You should be willing to accept the downside risks of owning equities in general and the underlying asset in particular, and the risk of losing a significant portion or all of your initial investment.

¨

There is no affiliation between the underlying asset issuer and UBS, and UBS is not responsible for any disclosure by such issuer — We are not affiliated with the underlying asset issuer. We and our affiliates may currently, or from time to time in the future engage in business with the underlying asset issuer. However, we are not affiliated with the underlying asset issuer and are not responsible for such underlying asset issuer’s public disclosure of information, whether contained in SEC filings or otherwise. You, as an investor in the Notes, should conduct your own investigation into the underlying asset and the underlying asset issuer. The underlying asset issuer is not involved in the Notes offered hereby in any way and has no obligation to take your interests into consideration for any reason, including when taking any corporate actions that might affect the market value of, and return on, your Notes.

Estimated Value Considerations

¨

The issue price you pay for the Notes will exceed their estimated initial value — The issue price you pay for the Notes will exceed their estimated initial value as of the trade date due to the inclusion in the issue price of the underwriting discount, hedging costs, issuance and other costs and projected profits. As of the close of the relevant markets on the trade date, we will determine the estimated initial value of the Notes by reference to our internal pricing models and it will be set forth in the final pricing supplement. The pricing models used to determine the estimated initial value of the Notes incorporate certain variables, including the level and volatility of the underlying asset, any expected dividends on the underlying asset, prevailing interest rates, the term of the Notes and our internal funding rate. Our internal funding rate is typically lower than the rate we would pay to issue conventional fixed or floating rate debt securities of a similar term. The underwriting discount, hedging costs, issuance and other costs, projected profits and the difference in rates will reduce the economic value of the Notes to you. Due to these factors, the estimated initial value of the Notes as of the trade date will be less than the issue price you pay for the Notes.

¨

The estimated initial value is a theoretical price; the actual price at which you may be able to sell your Notes in any secondary market (if any) at any time after the trade date may differ from the estimated initial value — The value of your Notes at any time will vary based on many factors, including the factors described above and in “— Risks Relating to Characteristics of the Underlying Asset — Single equity risk” above and is impossible to predict. Furthermore, the pricing models that we use are proprietary and rely in part on certain assumptions about future events, which may prove to be incorrect. As a result, after the trade date, if you attempt to sell the Notes in the secondary market, the actual value you would receive may differ, perhaps materially, from the estimated initial value of the Notes determined by reference to our internal pricing models. The estimated initial value of the Notes does not represent a minimum or maximum price at which we or any of our affiliates would be willing to purchase your Notes in any secondary market at any time.

¨

Our actual profits may be greater or less than the differential between the estimated initial value and the issue price of the Notes as of the trade date — We may determine the economic terms of the Notes, as well as hedge our obligations, at least in part, prior to the trade date. In addition, there may be ongoing costs to us to maintain and/or adjust any hedges and such hedges are often imperfect. Therefore, our actual profits (or potentially, losses) in issuing the Notes cannot be determined as of the trade date and any such differential between the estimated initial value and the issue price of the Notes as of the trade date does not reflect our actual profits. Ultimately, our actual profits will be known only at the maturity of the Notes.

Risks Relating to Liquidity
and Secondary Market price Considerations

¨

There may be little or no secondary market for the Notes — The Notes will not be listed or displayed on any securities exchange or any electronic communications network. There can be no assurance that a secondary market for the Notes will develop. UBS Securities LLC and its affiliates intend, but are not required, to make a market in the Notes and may stop making a market at any time. If you are able to sell your Notes prior to maturity you may have to sell them at a substantial loss. The estimated initial value of the Notes does not represent a minimum or maximum price at which we or any of our affiliates would be willing to purchase your Notes in any secondary market at any time.

¨

The price at which UBS Securities LLC and its affiliates may offer to buy the Notes in the secondary market (if any) may be greater than UBS’ valuation of the Notes at that time, greater than any other secondary market prices provided by unaffiliated dealers (if any) and, depending on your broker, greater than the valuation provided on your customer account statements — For a limited period of time following the issuance of the Notes, UBS Securities LLC or its affiliates may offer to buy or sell such Notes at a price that exceeds (i) our valuation of the Notes at that time based on our internal pricing models, (ii) any secondary market prices provided by unaffiliated dealers (if any) and (iii) depending on your broker, the valuation provided on customer account statements. The price that UBS Securities LLC may initially offer to buy such Notes following issuance will exceed the valuations indicated by our internal pricing models due to the inclusion for a limited period of time of the aggregate value of the underwriting discount, hedging costs, issuance costs and theoretical projected trading profit. The portion of such amounts included in our price will decline to zero on a straight line basis over a period ending no later than the date specified under “Supplemental Plan of Distribution (Conflicts of Interest); Secondary Markets (if any).” Thereafter, if UBS Securities LLC or an affiliate makes secondary markets in the Notes, it will do so at prices that reflect our estimated value determined by reference to our internal pricing models at that time. The temporary positive differential relative to our internal pricing models arises from requests from and arrangements made by UBS Securities LLC with the selling agents of structured debt securities such as the Notes. As described above, UBS Securities LLC and its affiliates intend, but are not required, to make a market for the Notes and may stop making a market at any time. The price at which UBS Securities LLC or an affiliate may make secondary markets at any time (if at all) will also reflect its then current bid-ask spread for similar sized trades of structured debt securities. UBS Securities LLC reflects this temporary positive differential on its customer statements. Investors should inquire as to the valuation provided on customer account statements provided by unaffiliated dealers.

¨

Economic and market factors affecting the terms and market price of Notes prior to maturity — Because structured notes, including the Notes, can be thought of as having a debt component and a derivative component, factors that influence the values of debt instruments and options and other derivatives will also affect the terms and features of the Notes at issuance and the market price of the Notes prior to maturity. These factors include the level of the underlying asset; the volatility of the underlying asset; any expected dividends on the underlying asset; the time remaining to the maturity of the Notes; interest rates in the markets; geopolitical conditions and economic, financial, political, force majeure and regulatory or judicial events; the creditworthiness of UBS; the then current bid-ask spread for the Notes and the factors discussed under “—Risks Relating to Hedging Activities and Conflicts of Interest — Potential conflicts of interest” below. These and other factors are unpredictable and interrelated and may offset or magnify each other.

¨

Impact of fees and the use of internal funding rates rather than secondary market credit spreads on secondary market prices — All other things being equal, the use of the internal funding rates described above under “— Estimated Value Considerations” as well as the inclusion in the issue price of the underwriting discount, hedging costs, issuance and other costs and any projected profits are, subject to the temporary mitigating effect of UBS Securities LLC’s and its affiliates’ market making premium, expected to reduce the price at which you may be able to sell the Notes in any secondary market.

Risks Relating to Hedging Activities
and Conflicts of Interest

¨

Potential conflicts of interest — UBS and its affiliates may engage in business with the underlying asset issuer, which may present a conflict between the interests of UBS and you, as a holder of the Notes. There are also potential conflicts of interest between you and the calculation agent, which will be an affiliate of UBS. The calculation agent will determine whether the contingent coupon is payable to you on any coupon payment date, whether the Notes are subject to an automatic call and the payment at maturity of the Notes, if any, based on observed closing levels of the underlying asset. The calculation agent can postpone the determination of the terms of the Notes if a market disruption event occurs or is continuing on the trade date, any observation date or the final valuation date. As UBS determines the economic terms of the Notes, including the contingent coupon rate, share delivery amount, call threshold level, downside threshold and coupon barrier, and such terms include the underwriting discount, hedging costs, issuance and other costs and projected profits, the Notes represent a package of economic terms. There are other potential conflicts of interest insofar as an investor could potentially get better economic terms if that investor entered into exchange-traded and/or OTC derivatives or other instruments with third parties, assuming that such instruments were available and the investor had the ability to assemble and enter into such instruments. Additionally, UBS and its affiliates act in various capacities with respect to the Notes, including as a principal, agent or dealer in connection with the sale of the Notes. Such affiliates, and any other third-party dealers, will derive compensation from the distribution of the Notes and such compensation may serve as an incentive to sell these Notes instead of other investments. Furthermore, given that UBS Securities LLC and its affiliates temporarily maintain a market making premium, it may have the effect of discouraging UBS Securities LLC and its affiliates from recommending sale of your Notes in the secondary market.

¨

The calculation agent can make antidilution and reorganization adjustments that affect the market value of, and return on, the Notes — For antidilution and reorganization events affecting the underlying asset, the calculation agent may make adjustments to the initial level, share delivery amount, call threshold level, coupon barrier, downside threshold and/or final level, as applicable, and any other term of the Notes. However, the calculation agent will not make an adjustment in response to every corporate event that could affect the underlying asset. If an event occurs that does not require the calculation agent to make an adjustment, the market value of, and return on, the Notes may be materially and adversely affected. In addition, all determinations and calculations concerning any such adjustments will be made by the calculation agent. You should be aware that the calculation agent may make any such adjustment, determination or calculation in a manner that differs from that discussed in the accompanying product supplement or herein as necessary to achieve an equitable result. Following certain reorganization events relating to the underlying asset issuer where such issuer is not the surviving entity, the determination as to whether the contingent coupon is payable to you on any coupon payment date, whether the Notes are subject to an automatic call or any payment at maturity may be based on the equity security of a successor to the underlying asset issuer in combination with any cash or any other assets distributed to holders of the underlying asset in such reorganization event. If the underlying asset issuer becomes subject to (i) a reorganization event whereby the underlying asset is exchanged solely for cash, (ii) a merger or consolidation with UBS or any of its affiliates, or (iii) the underlying asset is delisted or otherwise suspended from trading, the determination as to whether the

contingent coupon is payable to
you on any coupon payment date, whether the Notes are subject to an automatic call or any payment at maturity may be based on a substitute
security. Accordingly, at maturity you may receive shares of a security other than the original underlying asset. Further, if the underlying
asset is replaced or substituted by a security issued by a non-U.S. company that is traded on a non-U.S. exchange, we will pay, in lieu
of delivery of any such security, an amount in cash (payable in U.S. dollars) equal to the value thereof, as determined by the calculation
agent. The occurrence of any antidilution or reorganization event and the consequent adjustments may materially and adversely affect the
value of, and return on, the Notes. For more information, see the sections “General Terms of the Securities — Antidilution
Adjustments for Securities Linked to an Underlying Equity or Equity Basket Asset” and “— Reorganization Events
for Securities Linked to an Underlying Equity or Equity Basket Asset” in the accompanying product supplement.

¨

Potential UBS impact on price — Trading or transactions by UBS or its affiliates in the underlying asset, listed and/or over-the-counter options, futures, exchange-traded funds or other instruments with returns linked to the performance of the underlying asset, may adversely affect the level of the underlying asset and, therefore, the market value of, and return on, the Notes.

¨

Potentially inconsistent research, opinions or recommendations by UBS — UBS and its affiliates publish research from time to time on financial markets and other matters that may influence the value of, and return on, the Notes, or express opinions or provide recommendations that are inconsistent with purchasing or holding the Notes. Any research, opinions or recommendations expressed by UBS or its affiliates may not be consistent with each other and may be modified from time to time without notice. Investors should make their own independent investigation of the merits of investing in the Notes and the underlying asset.

Risks Relating to General Credit
Characteristics

¨

Credit risk of UBS — The Notes are unsubordinated, unsecured debt obligations of UBS and are not, either directly or indirectly, an obligation of any third party. Any payment or delivery to be made on the Notes, including any repayment of principal, depends on the ability of UBS to satisfy its obligations as they come due. As a result, UBS’ actual and perceived creditworthiness may affect the market value of the Notes. If UBS were to default on its obligations, you may not receive any payments or deliveries owed to you under the terms of the Notes and you could lose all of your initial investment.

¨

The Notes are not bank deposits — An investment in the Notes carries risks which are very different from the risk profile of a bank deposit placed with UBS or its affiliates. The Notes have different yield and/or return, liquidity and risk profiles and would not benefit from any protection provided to deposits.

¨

If UBS experiences financial difficulties, FINMA has the power to open restructuring or liquidation proceedings in respect of, and/or impose protective measures in relation to, UBS, which proceedings or measures may have a material adverse effect on the terms and market value of the Notes and/or the ability of UBS to make payments or deliveries thereunder — The Swiss Financial Market Supervisory Authority (“FINMA”) has broad statutory powers to take measures and actions in relation to UBS if (i) it concludes that there is justified concern that UBS is over-indebted or has serious liquidity problems or (ii) UBS fails to fulfill the applicable capital adequacy requirements (whether on a standalone or consolidated basis) after expiry of a deadline set by FINMA. If one of these pre-requisites is met, FINMA is authorized to open restructuring proceedings or liquidation (bankruptcy) proceedings in respect of, and/or impose protective measures in relation to, UBS. The Swiss Banking Act grants significant discretion to FINMA in connection with the aforementioned proceedings and measures. In particular, a broad variety of protective measures may be imposed by FINMA, including a bank moratorium or a maturity postponement, which measures may be ordered by FINMA either on a stand-alone basis or in connection with restructuring or liquidation proceedings. The resolution regime of the Swiss Banking Act is further detailed in Ordinance of 30 August 2012 of FINMA on the Insolvency of Banks and Securities Dealers, as amended (the “Swiss Banking Insolvency Ordinance”). In restructuring proceedings, FINMA, as resolution authority, is competent to approve the resolution plan. The resolution plan may, among other things, provide for (a) the transfer of all or a portion of UBS’ assets, debts, other liabilities and contracts (which may or may not include the contractual relationship between UBS and the holders of Notes) to another entity, (b) a stay (for a maximum of two business days) on the termination of contracts to which UBS is a party, and/or the exercise of (w) rights to terminate, (x) netting rights, (y) rights to enforce or dispose of collateral or (z) rights to transfer claims, liabilities or collateral under contracts to which UBS is a party, (c) the conversion of UBS’ debt and/or other obligations, including its obligations under the Notes, into equity (a “debt-to-equity” swap), and/or (d) the partial or full write-off of obligations owed by UBS (a “write-off”), including its obligations under the Notes. The Swiss Banking Insolvency Ordinance provides that a debt-to-equity swap and/or a write-off of debt and other obligations (including the Notes) may take place only after (i) all debt instruments issued by UBS qualifying as additional tier 1 capital or tier 2 capital have been converted into equity or written-off, as applicable, and (ii) the existing equity of UBS has been fully cancelled. While the Swiss Banking Insolvency Ordinance does not expressly address the order in which a write-off of debt instruments other than debt instruments qualifying as additional tier 1 capital or tier 2 capital should occur, it states that debt-to-equity swaps should occur in the following order: first, all subordinated claims not qualifying as regulatory capital; second, all other claims not excluded by law from a debt-to-equity swap (other than deposits); and third, deposits (in excess of the amount privileged by law). However, given the broad discretion granted to FINMA as the resolution authority, any restructuring plan in respect of UBS could provide that the claims under or in connection with the Notes will be partially or fully converted into equity or written-off, while preserving other obligations of UBS that rank pari passu with, or even junior to, UBS’ obligations under the Notes. Consequently, the exercise of any such powers by FINMA or any suggestion of any such exercise could materially adversely affect the rights of holders of the Notes, the price or value of their investment in the Notes and/or the ability of UBS to satisfy its obligations under the Notes and could lead to holders losing some or all of their investment in the Notes. In the case of restructuring proceedings with respect to a systemically important Swiss bank (such as UBS), the creditors whose claims are affected by the restructuring plan will not have a right to vote on, reject, or seek the suspension of the restructuring plan. In addition, if a restructuring plan has been approved by FINMA, the rights

of a creditor to seek judicial review
of the restructuring plan (e.g., on the grounds that the plan would unduly prejudice the rights of holders of Notes or otherwise be in
violation of the Swiss Banking Act) are very limited. In particular, a court may not suspend the implementation of the restructuring plan.
Furthermore, even if a creditor successfully challenges the restructuring plan, the court can only require the relevant creditor to be
compensated ex post and there is currently no guidance as to on what basis such compensation would be calculated or how it would be funded.

Risks Relating to U.S. Federal
Income Taxation

¨

Uncertain tax treatment — Significant aspects of the tax treatment of the Notes are uncertain. You should consult your tax advisor about your tax situation. See “What Are the Tax Consequences of the Notes?” herein and “Material U.S. Federal Income Tax Consequences”, including the section “— Securities Treated as Prepaid Derivatives or Prepaid Forwards with Associated Contingent Coupons”, in the accompanying product supplement.

Hypothetical
Examples of How the Notes Might Perform

The below examples are based on hypothetical terms.
The actual terms will be set on the trade date and will be indicated on the cover of the final pricing supplement.

The examples below illustrate the payment or delivery upon
an automatic call or at maturity, as applicable, for a $1,000 Note on a hypothetical offering of the Notes, with the following assumptions
(amounts may have been rounded for ease of reference):

Principal Amount:	$1,000
Term:	Approximately 2 years
Contingent Coupon Rate:	6.00% per annum (or 1.50% per quarter)
Contingent Coupon:	$15.00 per quarter
Observation Dates:	Quarterly (callable after 6 months)
Initial Level:	$22.00
Call Threshold Level:	$22.00 (which is equal to 100.00% of the Initial Level)
Coupon Barrier:	$12.10 (which is equal to 55.00% of the Initial Level)
Downside Threshold:	$12.10 (which is equal to 55.00% of the Initial Level)
Share Delivery Amount:	45.4545

Example 1 — The Closing Level of the Underlying
Asset is equal to or greater than the Call Threshold Level on the Observation Date corresponding to the first potential Call Settlement
Date.

Date	Closing Level	Payment (per Note)
First Observation Date	$24.20 (equal to or greater than Call Threshold Level and Coupon Barrier)	$15.00 (Contingent Coupon – Not Callable)
Second Observation Date	$22.44 (equal to or greater than Call Threshold Level and Coupon Barrier)	$1,015.00 (Call Settlement Amount)
	Total Payment:	$1,030.00 (3.00% total return)

Because the Notes are subject to an automatic call on the first
potential call settlement date (which is approximately 6 months after the trade date), UBS will pay you on the call settlement date a
total of $1,015.00 per Note (reflecting your principal amount plus the applicable contingent coupon). When added to the contingent coupon
of $15.00 received in respect of the prior observation date, UBS will have paid you a total of $1,030.00 per Note, for a total return
of 3.00% on the Notes. You will not receive any further payments on the Notes.

Example 2 — The Notes are NOT subject to an Automatic Call and the
Final Level is equal to or greater than the Downside Threshold and Coupon Barrier.

Date	Closing Level	Payment (per Note)
First Observation Date	$16.06 (equal to or greater than Coupon Barrier; less than Call Threshold Level)	$15.00 (Contingent Coupon)
Second through Seventh Observation Date	Various (all less than Call Threshold Level and Coupon Barrier)	$0.00
Final Valuation Date	$17.05 (equal to or greater than Coupon Barrier and Downside Threshold)	$1,015.00 (Payment at Maturity)
	Total Payment:	$1,030.00 (3.00% total return)

Because the Notes are not subject to an automatic call and
the final level is equal to or greater than the downside threshold, UBS will pay you a cash payment per Note at maturity equal to the
principal amount, in addition to any contingent coupon otherwise due on the maturity date. Because the final level was also equal to or
greater than the coupon barrier, a contingent coupon will be paid with respect to the final valuation date. At maturity, UBS will pay
you a total of $1,015.00 per Note (reflecting your principal amount plus the applicable contingent coupon). When added to the contingent
coupon of $15.00 received in respect of the prior observation dates, UBS will have paid you a total of $1,030.00 per Note, for a total
return of 3.00% on the Notes.

Example 3 — The Notes are NOT subject to an Automatic Call and the
Final Level is less than the Downside Threshold.

Date	Closing Level	Payment (per Note)
First Observation Date	$18.04 (equal to or greater than Coupon Barrier; less than Call Threshold Level)	$15.00 (Contingent Coupon)
Second through Seventh Observation Date	Various (all less than Call Threshold Level and Coupon Barrier)	$0.00
Final Valuation Date	$8.80 (less than Coupon Barrier and Downside Threshold)	Share Delivery Amount = $8.80 x 45.4545 = $400.00*
	Total Payment and/or Delivery:	$415.00 (58.50% loss)

* Represents the approximate
cash value of the share delivery amount on the final valuation date. Because the Notes are physically settled, the actual value received
and the total return on the Notes at maturity depends on the level of the underlying asset on the maturity date.

Because the Notes are not subject to an automatic call and
the final level is less than the downside threshold, at maturity UBS will deliver the share delivery amount (with cash paid in lieu of
any fractional share, equal to the product of such fractional share and the final level). When added to the contingent coupon of $15.00
received in respect of the prior observation dates, the value as of the final valuation date of the share delivery amount and the contingent
coupon received from UBS would be worth a total of $415.00 per Note, for a loss on the Notes of 58.50%.

Investors should note that, in the event that the final
level is less than the downside threshold, any decline of the level of the underlying asset from the final valuation date to the maturity
date will cause your return on the Notes to be less than the return you would have received had we instead paid you an amount in cash
equal to the share delivery amount.

Investing in the Notes involves significant risks. The
Notes differ from ordinary debt securities in that UBS is not necessarily obligated to repay the full amount of your initial investment.
If the Notes are not subject to an automatic call, you may lose a significant portion or all of your initial investment. Specifically,
if the Notes are not subject to an automatic call and the final level is less than the downside threshold, you will receive the share
delivery amount, the value of which is expected to be worth significantly less than the principal amount, resulting in a loss of a significant
portion or all of your initial investment. In this scenario, the percentage loss on your initial investment as of the final valuation
date will be equal to the percentage decline of the underlying asset from the initial level to the final level.

Any payment or delivery on the Notes, including any payments
in respect of an automatic call, contingent coupon or any repayment of principal, is subject to the creditworthiness of UBS. If UBS were
to default on its obligations, you may not receive any payments or deliveries owed to you under the Notes and you could lose all of your
initial investment.

Information
About the Underlying Asset

All disclosures contained in this document regarding the
underlying asset are derived from publicly available information. UBS has not conducted any independent review or due diligence of any
publicly available information with respect to the underlying asset. You should make your own investigation into the underlying asset.

Included below is a brief description of the underlying asset
issuer. This information has been obtained from publicly available sources. Set forth below is a graph that illustrates the past performance
for the underlying asset. The information given below is for the period indicated. We obtained the past performance information set forth
below from Bloomberg Professional^® service (“Bloomberg”) without independent verification. You should not take
the historical levels of the underlying asset as an indication of future performance.

The underlying asset is registered under the Securities Act
of 1933, the Securities Exchange Act of 1934 and/or the Investment Company Act of 1940, each as amended. Companies with securities registered
with the SEC are required to file financial and other information specified by the SEC periodically. Information filed by the underlying
asset issuer with the SEC can be reviewed electronically through a website maintained by the SEC. The address of the SEC’s website
is http://www.sec.gov. Information filed with the SEC can be located by reference to its SEC file number provided below. In addition,
information filed with the SEC can be inspected and copied at the Public Reference Section of the SEC, 100 F Street, N.E., Room 1580,
Washington, D.C. 20549. Copies of this material can also be obtained from the Public Reference Section, at prescribed rates.

JetBlue Airways Corporation

According to publicly available information, JetBlue Airways
Corporation (“JetBlue”) is a passenger carrier airline that provides air transportation services across various destinations
in the United States, the Caribbean and Latin America. Information filed by JetBlue with the SEC can be located by reference to its SEC
file number: 000-49728, or its CIK Code: 0001158463. JetBlue’s common stock is listed on the Nasdaq Global Select Market under the
ticker symbol “JBLU”.

Information from outside sources is not incorporated by reference
in, and should not be considered part of, this document or any document incorporated herein by reference. UBS has not conducted any independent
review or due diligence of any publicly available information with respect to the underlying asset.

Historical Information

The graph below illustrates the performance of JetBlue’s
common stock from January 1, 2011 through April 5, 2021, based on the daily closing levels as reported by Bloomberg, without independent
verification. UBS has not conducted any independent review or due diligence of any publicly available information obtained from Bloomberg.
The closing level of JetBlue’s common stock on April 5, 2021 was $21.17 (the “hypothetical initial level”). The dotted
lines respectively represent the hypothetical call threshold level of $21.17, which is equal to 100.00% of the hypothetical initial level,
and the hypothetical coupon barrier and hypothetical downside threshold of $11.64, which is equal to 55.00% of the hypothetical initial
level. The actual initial level, call threshold level, coupon barrier and downside threshold will be determined on the trade date. Past
performance of the underlying asset is not indicative of the future performance of the underlying asset during the term of the Notes.

 

What
Are the Tax Consequences of the Notes?

The U.S. federal income tax consequences of your investment
in the Notes are uncertain. There are no statutory provisions, regulations, published rulings or judicial decisions addressing the characterization
for U.S. federal income tax purposes of securities with terms that are substantially the same as the Notes. Some of these tax consequences
are summarized below, but we urge you to read the more detailed discussion in “Material U.S. Federal Income Tax Consequences”,
including the section “— Securities Treated as Prepaid Derivatives or Prepaid Forwards with Associated Contingent Coupons”,
in the accompanying product supplement and to discuss the tax consequences of your particular situation with your tax advisor. This discussion
is based upon the U.S. Internal Revenue Code of 1986, as amended (the “Code”), final, temporary and proposed U.S. Department
of the Treasury (the “Treasury”) regulations, rulings and decisions, in each case, as available and in effect as of the date
hereof, all of which are subject to change, possibly with retroactive effect. Tax consequences under state, local and non-U.S. laws are
not addressed herein. No ruling from the U.S. Internal Revenue Service (the “IRS”) has been sought as to the U.S. federal
income tax consequences of your investment in the Notes, and the following discussion is not binding on the IRS.

U.S. Tax Treatment. Pursuant to the terms of the Notes,
UBS and you agree, in the absence of a statutory or regulatory change or an administrative determination or judicial ruling to the contrary,
to characterize the Notes as prepaid derivative contracts with respect to the underlying asset. If your Notes are so treated, any contingent
coupon that is paid by UBS (including on the maturity date or call settlement date) should be included in your income as ordinary income
in accordance with your regular method of accounting for U.S. federal income tax purposes. In determining our information reporting obligations,
if any, we intend to treat the contingent coupons as ordinary income.

In addition, excluding amounts or proceeds attributable to
any contingent coupon, you should generally recognize gain or loss upon the taxable disposition of your Notes in an amount equal to the
difference between the amount you receive at such time (other than amounts or proceeds attributable to a contingent coupon or any amount
attributable to any accrued but unpaid contingent coupon) and the amount you paid for your Notes. Such gain or loss should generally be
long-term capital gain or loss if you have held your Notes for more than one year (otherwise such gain or loss would be short-term capital
gain or loss if held for one year or less). The deductibility of capital losses is subject to limitations. Although uncertain, it is possible
that proceeds received from the taxable disposition of your Notes prior to a coupon payment date, but that could be attributed to an expected
contingent coupon, could be treated as ordinary income. You should consult your tax advisor regarding this risk.

We will not attempt to ascertain whether the underlying asset
issuer would be treated as a “passive foreign investment company” (a “PFIC”) within the meaning of Section 1297
of the Code or as a “United States real property holding corporation” (a “USRPHC”) within the meaning of Section
897 of the Code. If any such entity were so treated, certain adverse U.S. federal income tax consequences might apply, to a U.S. holder
in the case of a PFIC and to a non-U.S. holder in the case of a USRPHC, upon the taxable disposition of a Note. Both U.S. holders and
non-U.S. holders should refer to information filed with the SEC or the equivalent governmental authority by any such entity and consult
their tax advisors regarding the possible consequences to them in the event that any such entity is or becomes a PFIC or USRPHC.

This discussion does not address the U.S. federal income
tax consequences to you of holding or disposing of any shares of the underlying asset that you may receive in connection with your investment
in the Notes. If you receive the share delivery amount, certain adverse U.S. federal income (and other) tax consequences might apply to
you. In general, your holding period in shares of the underlying asset received in connection with your investment in the Notes will begin
the day after you beneficially receive such shares. The IRS may treat the receipt of shares at maturity as a taxable settlement of the
Notes followed by a purchase of the shares of the underlying asset pursuant to the original terms of the Notes. If the receipt of shares
of the underlying asset is so treated, (i) you should recognize capital gain or loss equal to the fair market value of the shares received
at such time plus the cash you receive in lieu of a fractional share and the cash previously received (and not included in income), if
any, and the amount you paid for your Note, and (ii) you should take a basis in such shares in an amount equal to their fair market value
at such time. You should refer to information filed with the SEC or another governmental authority by the underlying asset issuer and
consult your tax advisor regarding possible tax consequences to you of acquiring, holding or otherwise disposing of the underlying asset.

Based on certain factual representations received from
us, our special U.S. tax counsel, Cadwalader, Wickersham & Taft LLP, is of the opinion that it would be reasonable to treat your Notes
in the manner described above. However, because there is no authority that specifically addresses the tax treatment of the Notes, it is
possible that your Notes could alternatively be treated for tax purposes as a single contingent payment debt instrument or pursuant to
some other characterization, such that the timing and character of your income from the Notes could differ materially and adversely from
the treatment described above, as described further under “Material U.S. Federal Income Tax Consequences”, including the section
“— Securities Treated as Prepaid Derivatives or Prepaid Forwards with Associated Contingent Coupons” in the accompanying
product supplement.

Except to the extent otherwise required by law, UBS intends
to treat your Notes for U.S. federal income tax purposes in accordance with the treatment described above and under “Material U.S.
Federal Income Tax Consequences — Securities Treated as Prepaid Derivatives or Prepaid Forwards with Associated Contingent
Coupons” in the accompanying product supplement unless and until such time as the IRS and the Treasury determine that some other
treatment is more appropriate.

Notice 2008-2. In 2007, the IRS released a notice
that may affect the taxation of holders of the Notes. According to Notice 2008-2, the IRS and the Treasury are actively considering whether
the holder of an instrument such as the Notes should be required to accrue ordinary income on a current basis. It is not possible to determine
what guidance they will ultimately issue, if any. It is possible, however, that under such guidance, holders of the Notes will ultimately
be required to accrue income currently in excess of any receipt of contingent coupons and this could be applied on a retroactive basis.
The IRS and the Treasury are also considering other relevant issues, including whether additional gain or loss from such instruments should
be treated as ordinary or capital, whether non-U.S. holders of such instruments should be subject to withholding tax on any deemed income
accruals, and whether the special “constructive ownership rules” of Section 1260 of the Code should be applied to such instruments.
Both U.S. and non-U.S. holders are urged to consult their tax advisors concerning the significance, and potential impact of the above
considerations.

Medicare Tax on Net Investment Income. U.S. holders
that are individuals, estates or certain trusts are subject to an additional 3.8% tax on all or a portion of their “net investment
income,” which may include any income or gain realized with respect to the Notes, to the extent of their net investment income that
when added to their other modified adjusted gross income, exceeds $200,000 for an unmarried individual, $250,000 for a married taxpayer
filing a joint return (or a surviving spouse), $125,000 for a married individual filing a separate return or the dollar amount at which
the highest tax bracket begins for an estate or trust. The 3.8% Medicare tax is determined in a different manner than the income tax.
U.S. holders should consult their tax advisors as to the consequences of the 3.8% Medicare tax.

Specified Foreign Financial Assets. U.S. holders may
be subject to reporting obligations with respect to their Notes if they do not hold their Notes in an account maintained by a financial
institution and the aggregate value of their Notes and certain other “specified foreign financial assets” (applying certain
attribution rules) exceeds an applicable threshold. Significant penalties can apply if a U.S. holder is required to disclose its Notes
and fails to do so.

Non-U.S. Holders. The U.S. federal income tax treatment
of the contingent coupons is unclear. Subject to the discussions below with respect to Section 871(m) of the Code and FATCA (as defined
below), our special U.S. tax counsel is of the opinion that contingent coupons paid to a non-U.S. holder that provides us (and/or the
applicable withholding agent) with a fully completed and validly executed applicable IRS Form W-8 should not be subject to U.S. withholding
tax and we do not intend to withhold any tax on contingent coupons. However, it is possible that the IRS could assert that such payments
are subject to U.S. withholding tax, or that another withholding agent may otherwise determine that withholding is required, in which
case the other withholding agent may withhold up to 30% on such payments (subject to reduction or elimination of such withholding tax
pursuant to an applicable income tax treaty). We will not pay any additional amounts in respect of such withholding. Subject to Section
897 of the Code, discussed above, and Section 871(m) of the Code, discussed below, gain realized from the taxable disposition or maturity
of the Notes generally should not be subject to U.S. tax unless (i) such gain is effectively connected with a trade or business conducted
by the non-U.S. holder in the U.S., (ii) the non-U.S. holder is a non-resident alien individual and is present in the U.S. for 183 days
or more during the taxable year of such taxable disposition and certain other conditions are satisfied or (iii) the non-U.S. holder has
certain other present or former connections with the U.S.

If the Notes are physically settled by delivery to you of
a number of shares of the underlying asset equal to the share delivery amount, you may suffer adverse U.S. federal income tax consequences
if you hold such shares of the underlying asset. For instance, you may be subject to U.S. withholding tax on U.S.-source dividends in
respect of such underlying asset that you hold. Other adverse tax consequences are possible. You should carefully review the potential
tax consequences that are set forth in information filed with the SEC or another governmental authority by the underlying asset issuer
and consult your tax advisor concerning the application of U.S. federal income tax laws (or the laws of any other taxing jurisdiction)
to your beneficial ownership of any shares of the underlying asset received at maturity.

Section 871(m). A 30% withholding tax (which may be
reduced by an applicable income tax treaty) is imposed under Section 871(m) of the Code on certain “dividend equivalents”
paid or deemed paid to a non-U.S. holder with respect to a “specified equity-linked instrument” that references one or more
dividend-paying U.S. equity securities or indices containing U.S. equity securities. The withholding tax can apply even if the instrument
does not provide for payments that reference dividends. Treasury regulations provide that the withholding tax applies to all dividend
equivalents paid or deemed paid on specified equity-linked instruments that have a delta of one (“delta-one specified equity-linked
instruments”) issued after 2016 and to all dividend equivalents paid or deemed paid on all other specified equity-linked instruments
issued after 2018. However, the IRS has issued guidance that states that the Treasury and the IRS intend to amend the effective dates
of the Treasury regulations to provide that withholding on dividend equivalents paid or deemed paid will not apply to specified equity-linked
instruments that are not delta-one specified equity-linked instruments and are issued before January 1, 2023.

Based on our determination that the Notes are not “delta-one”
with respect to the underlying asset, our special U.S. tax counsel is of the opinion that the Notes should not be delta-one specified
equity-linked instruments and thus should not be subject to withholding on dividend equivalents. Our determination is not binding on the
IRS, and the IRS may disagree with this determination. Furthermore, the application of Section 871(m) of the Code will depend on our determinations
on the date the terms of the Notes are set. If withholding is required, we will not make payments of any additional amounts.

Nevertheless, after the date the terms are set, it is possible
that your Notes could be deemed to be reissued for tax purposes upon the occurrence of certain events affecting the underlying asset or
your Notes, and following such occurrence your Notes could be treated as delta-one specified equity-linked instruments that are subject
to withholding on dividend equivalents. It is also possible that withholding tax or other tax under Section 871(m) of the Code could apply
to the Notes under these rules if a non-U.S. holder enters, or has entered, into certain other transactions in respect of the underlying
asset or the Notes. A non-U.S. holder that enters, or has entered, into other transactions in respect of the underlying asset or the Notes
should consult its tax advisor regarding the application of Section 871(m) of the Code to its Notes in the context of its other transactions.

Because of the uncertainty regarding the application of
the 30% withholding tax on dividend equivalents to the Notes, you are urged to consult your tax advisor regarding the potential application
of Section 871(m) of the Code and the 30% withholding tax to an investment in the Notes.

Foreign Account Tax Compliance Act. The Foreign Account
Tax Compliance Act (“FATCA”) was enacted on March 18, 2010, and imposes a 30% U.S. withholding tax on “withholdable
payments” (i.e., certain U.S.-source payments, including interest (and original issue discount), dividends, other fixed or determinable
annual or periodical gain, profits, and income, and on the gross proceeds from a disposition of property of a type which can produce U.S.-source
interest or dividends) and “passthru payments” (i.e., certain payments attributable to withholdable payments) made to certain
foreign financial institutions (and certain of their affiliates) unless the payee foreign financial institution agrees (or

is required), among other things, to disclose the identity
of any U.S. individual with an account of the institution (or the relevant affiliate) and to annually report certain information about
such account. FATCA also requires withholding agents making withholdable payments to certain foreign entities that do not disclose the
name, address, and taxpayer identification number of any substantial U.S. owners (or do not certify that they do not have any substantial
U.S. owners) to withhold tax at a rate of 30%. Under certain circumstances, a holder may be eligible for refunds or credits of such taxes.

Pursuant to final and temporary Treasury regulations and
other IRS guidance, the withholding and reporting requirements under FATCA will generally apply to certain “withholdable payments”,
will not apply to gross proceeds on a sale or disposition, and will apply to certain foreign passthru payments only to the extent that
such payments are made after the date that is two years after final regulations defining the term “foreign passthru payment”
are published. If withholding is required, we (or the applicable paying agent) will not be required to pay additional amounts with respect
to the amounts so withheld. Foreign financial institutions and non-financial foreign entities located in jurisdictions that have an intergovernmental
agreement with the U.S. governing FATCA may be subject to different rules.

Investors should consult their tax advisors about the application
of FATCA, in particular if they may be classified as financial institutions (or if they hold their Notes through a foreign entity) under
the FATCA rules.

Proposed Legislation. In 2007, legislation was introduced
in Congress that, if it had been enacted, would have required holders of Notes purchased after the bill was enacted to accrue interest
income over the term of the Notes despite the fact that there may be no interest payments over the term of the Notes.

Furthermore, in 2013, the House Ways and Means Committee
released in draft form certain proposed legislation relating to financial instruments. If it had been enacted, the effect of this legislation
generally would have been to require instruments such as the Notes to be marked to market on an annual basis with all gains and losses
to be treated as ordinary, subject to certain exceptions.

It is not possible to predict whether any similar or identical
bills will be enacted in the future, or whether any such bill would affect the tax treatment of your Notes. You are urged to consult your
tax advisor regarding the possible changes in law and their possible impact on the tax treatment of your Notes.

Both U.S. and non-U.S. holders are urged to consult
their tax advisors concerning the application of U.S. federal income tax laws to their particular situations, as well as any tax consequences
of the purchase, beneficial ownership and disposition of the Notes, and any shares of the underlying asset received, arising under the
laws of any state, local, non-U.S. or other taxing jurisdiction.

Supplemental
Plan of Distribution (Conflicts of Interest); Secondary Markets (if any)

We will agree to sell to UBS Securities LLC, and UBS Securities
LLC will agree to purchase, all of the Notes at the issue price to the public less the underwriting discount indicated on the cover hereof.
UBS Securities LLC intends to resell the Notes to one or more third-party dealers at a discount from the issue price to the public equal
to the underwriting discount indicated on the cover hereof. Certain of such third-party dealers may resell the Notes to other securities
dealers at the issue price to the public less an underwriting discount of up to the underwriting discount indicated on the cover hereof.
Certain unaffiliated registered investment advisers or fee-based advisory accounts may purchase Notes from a third-party dealer at a purchase
price of at least $982.50 per Note, and such third-party dealer, with respect to such sales, may forgo some or all of the underwriting
discount. Additionally, we or one of our affiliates may pay a fee to an unaffiliated broker-dealer for providing certain electronic platform
services with respect to this offering.

Conflicts of Interest — UBS Securities
LLC is an affiliate of UBS and, as such, has a “conflict of interest” in this offering within the meaning of Financial Industry
Regulatory Authority, Inc. (“FINRA”) Rule 5121. In addition, UBS will receive the net proceeds (excluding the underwriting
discount) from the initial public offering of the Notes, thus creating an additional conflict of interest within the meaning of FINRA
Rule 5121. Consequently, the offering is being conducted in compliance with the provisions of FINRA Rule 5121. UBS Securities LLC is not
permitted to sell Notes in this offering to an account over which it exercises discretionary authority without the prior specific written
approval of the account holder.

UBS Securities LLC and its affiliates may offer to buy
or sell the Notes in the secondary market (if any) at prices greater than UBS’ internal valuation — The value of
the Notes at any time will vary based on many factors that cannot be predicted. However, the price (not including UBS Securities LLC’s
or any affiliates’ customary bid-ask spreads) at which UBS Securities LLC or any affiliate would offer to buy or sell the Notes
immediately after the trade date in the secondary market is expected to exceed the estimated initial value of the Notes as determined
by reference to our internal pricing models. The amount of the excess will decline to zero on a straight line basis over a period ending
no later than 6 months after the trade date, provided that UBS Securities LLC may shorten the period based on various factors, including
the magnitude of purchases and other negotiated provisions with selling agents. Notwithstanding the foregoing, UBS Securities LLC and
its affiliates intend, but are not required to make a market for the Notes and may stop making a market at any time. For more information
about secondary market offers and the estimated initial value of the Notes, see “Key Risks — Estimated Value Considerations”
and “— Risks Relating to Liquidity and Secondary Market price Considerations” herein.

Prohibition of Sales to EEA & UK Retail Investors —
The Notes are not intended to be offered, sold or otherwise made available to and should not be offered, sold or otherwise made available
to any retail investor in the European Economic Area (“EEA”). For these purposes, a retail investor means a person who is
one (or more) of: (i) a retail client as defined in point (11) of Article 4(1) of Directive 2014/65/EU, as amended (“MiFID II”);
(ii) a customer within the meaning of Directive 2002/92/EC, as amended, where that customer would not qualify as a professional client
as defined in point (10) of Article 4(1) of MiFID II; or (iii) not a qualified investor as defined in Directive 2003/71/EC, as amended.
Consequently, no key information document required by Regulation (EU) No 1286/2014 (as amended, the “EU PRIIPs Regulation”)
for offering or selling the Notes or otherwise making them available to retail investors in the EEA has been prepared and therefore offering
or selling the Notes or otherwise making them available to any retail investor in the EEA may be unlawful under the EU PRIIPs Regulation.

The Notes are not intended to be offered, sold or otherwise
made available to and should not be offered, sold or otherwise made available to any retail investor in the United Kingdom (the “UK”).
For these purposes, a retail investor in the UK means a person who is one (or more) of: (i) a retail client as defined in point (8) of
Article 2 of Regulation (EU) No 2017/565 as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018, subject
to amendments made by the Markets in Financial Instruments (Amendment) (EU Exit) Regulations 2018 (SI 2018/1403), as may be amended or
superseded from time to time (the “EUWA”); (ii) a customer within the meaning of the provisions of the Financial Services
and Markets Act 2000 (the “FSMA”) and any rules or regulations made under the FSMA to implement Directive (EU) 2016/97, where
that customer would not qualify as a professional client, as defined in point (8) of Article 2(1) of Regulation (EU) No 600/2014 as it
forms part of UK domestic law by virtue of the EUWA; or (iii) not a qualified investor as defined in Article 2 of the Prospectus Regulation
as it forms part of domestic law by virtue of the EUWA (“UK Prospectus Regulation”). Consequently, no key information document
required by the PRIIPs Regulation as it forms part of UK domestic law by virtue of the EUWA (the “UK PRIIPs Regulation”) for
offering or selling the Notes or otherwise making them available to retail investors in the UK has been prepared and therefore offering
or selling the Notes or otherwise making them available to any retail investor in the UK may be unlawful under the UK PRIIPs Regulation.